Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
Claire N HarrisonJyoti NangaliaRebecca BoucherAimee JacksonChristina YapJennifer O'SullivanSonia FoxIsaak AiltsAmylou C DueckHolly L GeyerRuben A MesaWilliam G DunnEugene NadezhdinNatalia Curto-GarciaAnna GreenBridget WilkinsJason CoppellJohn LaurieMamta GargJoanne EwingStephen KnapperJosephine CroweFrederick ChenIoannis KoutsavlisAnna GodfreySiamak AramiMark DrummondJennifer L ByrneFiona ClarkCarolyn Mead-HarveyElizabeth Joanna BaxterMary Frances Frances McMullinAdam J MeadPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The MAJIC-PV study demonstrates ruxolitinib treatment benefits HC-INT/RES PV patients with superior CR, and EFS as well as molecular response; importantly also demonstrating for the first time, to our knowledge, that molecular response is linked to EFS, PFS, and OS.
Keyphrases